# Biomarker Core

> **NIH NIH P30** · YALE UNIVERSITY · 2021 · $418,750

## Abstract

The Biomarker Core will play a key role in the proposed Yale ADRC by managing the Biospecimen
Repository consisting of both standard and novel biospecimens, and through the development and application
of cutting-edge proteomic and epigenetic assays and bioinformatics approaches to integrate high-dimensional
multi-omics data. Methods and biospecimens under the jurisdiction of the Yale ADRC Biomarker Core will
facilitate the development and validation of promising biomarkers of Alzheimer’s disease (AD) susceptibility,
improve AD risk prediction, and identify promising directions for development of targeted interventions. The
Biomarker Core will work closely with the Data Management and Statistics Core (DMSC) in the management
of the Biospecimens Repository. We will also facilitate the integration of multi-omics data with data generated
by the Clinical and Imaging Cores to assess and validate both standard and novel biomarkers aimed at
capturing AD heterogeneity, susceptibility, and progression. We will work with the DMSC to utilize statistical
modeling of cognitive trajectories and decline, and/or considerations of mortality selection or other biases when
evaluating the reliability, validity, and generalizability of AD-related biomarkers. Finally, we will work with the
Education Component and Outreach Core to facilitate training and outreach in AD Biomarker acquisition and
use. Specific Aims include: Aim 1: Manage Yale ADRC Biospecimen Repository. Working closely with the
Clinical, Neuropathology, and DMS Cores, and NCRAD, we will manage the Yale ADRC biorepository and
provide biospecimens to ADRC and non-ADRC investigators. Aim 2: Assess, track and validate biofluid and
tissue biomarkers of AD. We will use standardized ELISA-based assays for Abeta1-40, Abeta1-42, t-tau and p-
tau in CSF in existing and future biofluid samples from Yale ADRC Biorepository, as well as utilize state-of-the-
art targeted mass spectrometric assays to analyze selected biomarkers in biofluid and brain tissue from the
Yale ADRC Biorepository and other ADRC-affiliated research projects. Aim 3: Assess, track and validate
systems-level biomarkers based on high-dimensional omics data. We will assess DNA methylation (DNAm) in
biofluids from the Yale ADRC Biorepository and other ADRC-affiliated research projects, and use it to calculate
both validated and novel biomarker measures of epigenetic age and AD heterogeneity. Working with the
DMSC, we will use systems biology approaches to integrate the DNAm and proteomic data with data available
via the Clinical and Imaging Cores. Aim 4: Facilitate training and Outreach in AD Biomarker acquisition and
use.

## Key facts

- **NIH application ID:** 10180855
- **Project number:** 5P30AG066508-02
- **Recipient organization:** YALE UNIVERSITY
- **Principal Investigator:** ANGUS C. NAIRN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $418,750
- **Award type:** 5
- **Project period:** 2020-06-15 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10180855

## Citation

> US National Institutes of Health, RePORTER application 10180855, Biomarker Core (5P30AG066508-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10180855. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*